pharmaphorum
OCTOBER 1, 2021
KY1005 – now renamed amlitelimab – is one of a handful of new drugs targeting OX40 ligand, an immune system regulator delivered by intravenous infusion once every 28 days. Now, it says the drug has delivered “exciting” results in a proof-of-concept trial. It is also being developed in a subcutaneous formulation.
pharmaphorum
MAY 25, 2022
Vtama (tapinarof) – originally developed by GlaxoSmithKline – is a first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) and has been approved by the US regulator with a broad label spanning mild, moderate, and severe psoriasis and an unlimited duration of use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 12, 2021
Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.
The Pharma Data
AUGUST 1, 2021
Financial considerations AstraZeneca acquired global rights to Saphnelo through an exclusive license and collaboration agreement with Medarex, Inc. 4 Type I IFNs such as IFN-alpha, IFN-beta and IFN-kappa are cytokines involved in regulating the inflammatory pathways implicated in SLE.
pharmaphorum
JUNE 8, 2021
It’s the second unusual royalty-focused deal to be entered into by a biotech in the last few days, after MorphoSys signed over future revenues from out-licensed medicines to fund its $1.7 billion in 2019 in side deal to Bristol-Myers Squibb’s $74 billion takeover of Celgene enforced by antitrust regulators.
The Pharma Data
AUGUST 3, 2021
We expect that recovery in the dermatology segment will continue to progress over the coming quarters. In July, the FDA accepted the Biologics License Application and granted Priority Review for tezepelumab for the treatment of asthma. and continued geographic expansion, including the launch in China. Bemarituzumab. Tezepelumab.
The Pharma Data
JANUARY 13, 2021
(IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases. Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. Source link.
Expert insights. Personalized for you.
103 
Let's personalize your content